Oniria reports potential first-in-class TET2 activator with efficacy in leukemia and melanoma models
March 13, 2024
TET2 is a master epigenetic enzyme that converts 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), reprograming tumor cells and causing them to enter a dormant state.
